HAS
Hasbro, Inc.stockNASDAQ
At CloseNov 19, 2026 3:59:59 PM EST
114.74USD-3.291%(-3.90)1,368,212
After-hoursNov 19, 2026 4:03:30 PM EST
114.00USD-0.641%(-0.74)
HAS Reddit Mentions by subreddit
Loading…
HAS Mentions × sentiment
Loading…
HAS Specific Mentions latest comments & posts
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123518863291941217)
>IRAN'S FOREIGN MINISTRY SPOKESMAN SAYS US CLAIMS TEHRAN IS DEVELOPING CHEMICAL AND BIOLOGICAL WEAPONS AIM TO STOKE FEAR AND JUSTIFY MILITARY ACTION
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123519098059640843)
>FED'S GOOLSBEE SAYS IT HAS NOT BEEN GOOD NEWS ON INFLATION FOR THE PAST FEW MONTHS AND THAT HE DOES NOT SEE INFLATION ON THE PATH BACK TO 2%, WITH PRICE PRESSURES COMING NOT JUST FROM OIL AND TARIFF SHOCKS BUT ALSO A SIZABLE DEMAND COMPONENT
sentiment -0.502
Agreed. This idiot is acting like a chargeback shouldn’t be possible - IT IS A LEGAL RIGHT WHEN FRAUD HAS BEEN COMMITTED.
I really feel for these people in jurisdictions where legislation does not clearly dictate that - at least in the US, it doesn’t matter if chargeback is or is not possible, if it’s fraud or theft, it is legally mandated the bank refunds according to whether the situation meets certain definitions.
sentiment -0.755
Welcome to the KANSAS CITY SHUFFLE - all of this is by design .. warrants are still hanging around like a bad rash so are you honestly still in DENIAL? So what they can’t “legally be brought back” according to AI. Didn’t RC specify this HAS NEVER BEEN DONE BEFORE? Let’s be real people
sentiment 0.445
MTG and Riftbound, Poke market is cooked and none plays with those game pieces just slabs and scams.
MTG and Riftbound they actually treat them like Game pieces and Riftbound is going to get a huge following while MTG is the nerds with money standard but Hasbro is going to milk it hard so might just be better to buy HAS or just pick cards off the reserve list to hold.
I know its sarcasm but legit can make some beer money off flipping cardboard if you know what you are doing.
sentiment 0.684
MANGO MAN HAS TO ADMIT THESE WOKE LIBS MAKING THE MOST DESIRABLE IPO ON THE MARKET LOLLLL
sentiment 0.477
Tweet Mirror:[DeItaone](https://twitter.com/DeItaone/status/2123478114852610427)
>TRUMP SAYS 'IN NO RUSH' TO MAKE DECISION ON IRAN: ISRAEL'S CHANNEL 12
Tweet Mirror:[VisualCap](https://twitter.com/VisualCap/status/2123477920102363170)
>Mapped: The Price of a Big Mac Around the World 🍔
>
>
>
>https://www.visualcapitalist.com/big-mac-costs-around-world-2026/
>
>[\[Twitter Image 1\]](https://pbs.twimg.com/media/HXgby_qXMAABT1H?format=webp&name=large)
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123477656708788612)
>THE US 10\-YEAR TIPS AUCTION DREW A HIGH YIELD OF 2\.903%, TAILING BY 0\.3 BASIS POINTS, WITH A BID\-TO\-COVER OF 2\.43 ON $19 BLN SOLD AND 90\.74% OF BIDS AWARDED AT THE HIGH\. PRIMARY DEALERS TOOK 6\.03%, DIRECT BIDDERS 25\.41% AND INDIRECT BIDDERS 68\.56%
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123476723333546230)
>ECB'S PANETTA SAYS POLICYMAKERS MUST STOP INFLATION FROM TAKING ROOT
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123476875741978629)
>JOB MARKET IS STABLE RIGHT NOW AND FED'S FAILURE HAS BEEN ON INFLATION, GOOLSBEE SAYS; STAGFLATION NOT SEEN AT PRESENT
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123477005102674243)
>TRUMP WEIGHS POSSIBLE ATTACK ON IRAN, AND TOUCHES ON DISAGREEMENTS WITHIN THE "CHANGE BLOC," ISRAEL'S CHANNEL 12 REPORTS
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123477091283021870)
>ECB'S PANETTA SAYS POLICYMAKERS MUST FIGHT INFLATION WITHOUT HURTING GROWTH TOO MUCH
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123477123902148990)
>FED'S GOOLSBEE SAYS THE FED CANNOT LOOK THROUGH TARIFFS IF THEY PERSIST
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/2123477173789172168)
>GOOLSBEE SAYS IMMIGRATION POLICY SHIFTS MEAN FED SHOULD GIVE MONTHLY JOBS DATA LESS WEIGHT AS BUSINESS CYCLE SIGNAL
sentiment -0.460
HOW IS IT POSSIBLE ANYONE HAS LOST MONEY ON ANTHROPIC. IT IPO FOR LIKE 89. YOU LITERALLY WOULD HAVE HAD TO BUY THE ABSOLUTE TOP TO LOSE HERE. LOL
sentiment -0.128
JEZUS BOEDDA MOHAMMED IF ANY OF YOU ARE REAL THIS V HAS TO V LIKE NO OTHER V HAS VD BEFORE
sentiment -0.296
NVDA HAS BROKEN THE 150 WALL
sentiment -0.590
HE HAS RETURNED!
WELCOME FUTURE BAGGYS!
sentiment 0.555
THE BLEEDING HAS ONLY JUST BEGUN
sentiment 0.000
THE KING HAS RETURNED
sentiment 0.000
Oh Mamer Su 😬 $AMD
HUNTERBOOK: WE BELIEVE AMD HAS ALSO ILLEGALLY SOLD CHIPS INTO CHINA
sentiment -0.340
https://imgur.com/a/k1gQ1Um
These are very special ingots not many made or many survive.
H Alvin Sharpe Tezcuco silver vintage ingot
🔥 2 oz class 999 silver
"Tezcuco," piece by H. Alvin Sharpe for WYES-TV as part of his Louisiana Landmarks series.
Tezcuco plantation house
• Markings: Bears the title "TEZCUCO", "H.A.S." initials, "WYES-TV", stamped studio/proof "ORIGINAL PATTERN," "PROOF," "UNIQUE,"
Very rare piece
555 ship on me
999 silver Gallier House WYES 🔥 HAS STUDIO PROOF SUPER TONER GALLIER HOUSE
999 silver 2 oz class but weight doesn’t matter.
389 ship on me
⚡️
Take both for 915 priority
Zelle
Venmo
Ppal GS plus 5% (least fav option)
sentiment -0.015
BREAKING: ROBERT PATTINSON HAS BEEN CHOSEN AS THE NEXT SENATE MAJORITY LEADER
sentiment 0.000
We have been talking a lot about Elite's pipeline on this board, but we still do not have a solid view of it. Elite has disclosed only part of it, and many products are still unnamed. So I have tried to build a list based on the medications coming off patent in the right time frame, matched to what management has told us on the calls, and I added the missing information: IQVIA sales and patent expiration dates.
I believe this belongs on the ELTP iHub page, as it contains valuable information for new and existing investors. Corrections and additions are welcome.
*Compiled from Elite's press releases and 8-Ks, the Nov 13, 2026 earnings call, IQVIA figures quoted by other generic makers, and FDA Orange Book patent data. Where Elite has NOT named the product, the brand shown is MY GUESS based on patent timing – it is not company information.*
**A QUICK WORD ON THE NUMBERS**
\- IQVIA measures U.S. sales at list price, before rebates. That is why these figures are higher than what the brand companies report.
\- Generics sell at a fraction of the brand price, so these numbers show the size of the prize, not Elite's future revenue.
\- The dates differ (some IQVIA figures are from 2020–2023), so treat older figures as approximate.
\- **Patent expiry is not the same as generic launch.** Most generics enter on dates negotiated in patent settlements, which can be earlier or later than the last patent.
**1. ANTICOAGULANTS (Pillar #1)**
**Anticoagulant #1 – generic ELIQUIS (apixaban), BMS / Pfizer**
\- **IQVIA:** **$26 BILLION** in U.S. brand sales (12 months to March 2026), as quoted by Elite in its June 1, 2026 8-K. A year earlier Elite cited $27B.
\- **Patents:** the compound patent (US 6,967,208) originally expired September 2022 and was extended to **November 2026**. Companies that settled with BMS/Pfizer can launch on **April 1, 2028**. Companies that did not settle face a formulation patent running to August 2031.
\- **Elite status:** ANDA filed June 1, 2026. FDA goal date March 2027, with only minor FDA comments so far. Hakim says Elite launches alongside the settled generics ("Yes, 100%").
**Anticoagulant #2 – my guess: generic XARELTO (rivaroxaban), J&J / Bayer**
\- **Sales:** about **$2.4 BILLION** U.S. sales in 2024 (company-reported, not IQVIA). IQVIA puts the 2.5 mg strength alone at about $446M.
\- **Patents:** generics of all strengths entered the U.S. market in **2025**. A dosing patent on the 2.5 mg strength runs to **2039** and is still in litigation.
\- **Elite status:** bioequivalence (BE) study to begin 1H 2027. Approval targeted for 2028. Elite would be a later entrant.
**2. CNS – EPILEPSY (Pillar #5)**
**Anticonvulsant – brand not disclosed by Elite**
\- **IQVIA:** **$840 MILLION** brand + generic sales (12 months to April 2026), per Elite's June 15, 2026 8-K.
\- **Patents:** not known, since the brand is not disclosed. IQVIA counts "brand and generic," so generics are already on the market.
\- **Elite status:** positive pivotal BE study June 2026. ANDA filing in Q1 2027.
**3. PAIN / OPIOIDS (Pillar #4)**
**Oxycodone ER – generic OXYCONTIN, Purdue**
\- **IQVIA:** **$720 MILLION** brand + generic (12 months to June 2023), per Elite. Back in 2016, OxyContin and its equivalents sold about $2.3B, so this market is shrinking.
\- **Patents:** the original OxyContin patent expired **April 2013**, but the FDA withdrew the original formula, so any generic must copy the abuse-deterrent version. Its patents are not in my research. What matters is Elite's settlement with Purdue: lawsuit dismissed June 12, 2026, with an agreed entry date (management: around **August 2027**).
\- **Elite status:** under FDA review since September 2023. FDA approval is the main hurdle (the FDA raised an abuse-deterrence question).
\- Abuse-deterrent tablets are hard to copy, so few competitors are likely, which usually means better pricing.
**4. TYPE 2 DIABETES (Pillar #3) – 4 products, none named by Elite**
*Hakim said the diabetes portfolio grew from 3 to 4 products. Elite commits to at least 1 BE study in 1H 2027 and predicts 2–3. The candidates below are the diabetes blockbusters going generic in the right time frame.*
**Candidate: JANUVIA (sitagliptin), Merck**
\- **IQVIA:** about **$5.8 BILLION** U.S. (MAT October 2023)
\- **Patents:** the key salt patent (US 7,326,708) expires **November 24, 2026**. Under settlements, generics launched early, in **May 2026** (about 25 generic makers settled).
**Candidate: JANUMET and JANUMET XR (sitagliptin + metformin), Merck**
\- **IQVIA:** Janumet about **$1.1 BILLION** (MAT September 2024); Janumet XR about **$270 MILLION** (12 months to May 2026)
\- **Patents:** same November 24, 2026 salt patent, plus a Janumet patent to **January 21, 2029**. Under settlements, Janumet generics launched in May 2026 and the first Janumet XR generic in July 2026.
**Candidate: FARXIGA (dapagliflozin), AstraZeneca**
\- **IQVIA:** about **$10.5 BILLION** U.S. (12 months to December 2025)
\- **Patents:** the compound patent (US 6,515,117) has **expired** (2025–2026 with pediatric extension). Method patents run to February 2027 and crystal-form patents to 2027–2030. Newer heart-failure and kidney-disease patents run to **2039–2041**, so generics may launch with those uses left off the label.
\- **Generic entry:** first generics approved **April 7, 2026** (Alembic, Lupin, Biocon, Aurobindo, Zydus), with shared 180-day exclusivity for the first filers.
**Candidate: JARDIANCE (empagliflozin) and combinations, Boehringer / Lilly**
\- **IQVIA:** about **$4.4 BILLION** U.S. for Jardiance (MAT March 2020 – an old figure; today's is likely higher). Glyxambi about $216M (MAT September 2025); Trijardy XR about $111M (MAT April 2024).
\- **Patents:** the compound patent (US 8,222,323) expired **January 2025**, but formulation and method-of-use patents run to **2034**. Boehringer has settled with generic makers on undisclosed terms.
\- **Generic entry:** not expected before **2029 or later**. 19 generic makers already hold tentative FDA approval.
**Candidate: TRADJENTA (linagliptin), Boehringer / Lilly**
\- **IQVIA:** not found
\- **Patents:** a process patent expired **November 2025**. Formulation and use patents run to **May 4, 2027**, and a method patent to **March 5, 2031**.
\- **Generic entry:** generic versions are FDA-approved, but the brand still sells at about $16.80 per tablet, so generic launch is still ahead.
**For scale:** IQVIA put the whole U.S. DPP-4 class (Januvia, Tradjenta and their combinations) at about **$9.5 BILLION** (MAT May 2024).
**5. CNS – PSYCHIATRY (Pillar #5)**
**New antipsychotic – not disclosed ("at the appropriate time")**
**Candidate: VRAYLAR (cariprazine), AbbVie**
\- **IQVIA:** about **$2.4 BILLION** U.S. (MAT July 2022 – AbbVie has grown it since)
\- **Patents:** last compound patent (US 7,737,142) expires **September 17, 2029**.
\- **Generic entry:** several generics already have FDA approval (Zydus 2022, Aurobindo December 2025), so launch timing depends on settlements.
**Candidate: REXULTI (brexpiprazole), Otsuka / Lundbeck**
\- **IQVIA:** about **$2 BILLION** U.S. (12 months to September 2024)
\- **Patents:** the compound patents (US 7,888,362, 8,349,840, 8,618,109) expired **April 12, 2026** (October 12, 2026 with pediatric exclusivity). A tablet patent runs to **April 2033**, and the last FDA exclusivity runs to 2028.
\- **Generic entry:** generics approved (Alembic January 2025), but launch timing depends on the remaining patent and exclusivity.
**6. ADHD (Pillar #2) – \~80% OF TODAY'S REVENUE**
\- Elite already sells generic Vyvanse, Adderall IR and Adderall XR. All three brands are already off patent. For reference, IQVIA sized the Vyvanse market at $4.3B, Adderall XR at $1.3B and Adderall IR at $361M when Elite launched them.
\- **Pipeline:** a possible BE study in 2027 to expand the ADHD line (product not disclosed).
\- Growth is limited mainly by DEA quotas, not demand.
**7. OTHER PENDING APPLICATION**
\- A dopamine-agonist ANDA, accepted by the FDA in December 2022, is still listed as pending in the 10-Q. Elite already launched generic Requip XL in August 2026, so this may be a second product.
**BOTTOM LINE**
\- The three products Elite HAS disclosed (anticoagulant #1, anticonvulsant, Oxy ER) carry about **$27.5 BILLION** of IQVIA brand sales.
\- If Elite's 4 diabetes products and the antipsychotic match the brands going generic between 2026 and 2031, the brand sales behind the pipeline run to tens of billions more.
\- **Timing works in Elite's favor:** Januvia, Janumet, Farxiga and Rexulti compound patents expired in 2025–2026; Tradjenta patents run to 2027–2031; Vraylar to 2029. Elite's BE studies in 2027 line up with that wave.
\- The catalysts are dated: Nasdaq listing targeted for March 2027, anticoagulant FDA date March 2027, anticonvulsant filing Q1 2027, BE studies 1H 2027, Eliquis launch April 2028. In Hakim's words: *"2027 is going to be the year of R&D and 2028 is the year of the second growth."*
\- **Reality check:** these are brand sizes. Generic prices fall sharply once many companies launch, and Elite will enter several of these markets after others. Elite's actual revenue will be a small fraction of these numbers. With a 10–20% share in a few large markets, though, that fraction is still big for a company with about $160M in annual revenue.
*My own research and opinion, based on Elite's filings, the Nov 13, 2026 call, published IQVIA data and FDA Orange Book patent listings. Brands marked as candidates are guesses, not company disclosures. Patent dates can change through litigation, extensions and settlements. Not investment advice – please do your own due diligence.*
GLTA
sentiment 0.998
BREAKING NEWS: SLS HAS INFORMED SHAREHOLDERS OF A MAJOR BREAKTHROUGH. ITS SAID TO BE CALLED ("THE EASY WAY OUT+1") AND THE ("ITS OVER-2") STIM INJECTION. WORKS REMARKABLEY WELL ON TESTED BERS THAT ARE GOING THROUGH DEPRESSION- BLACKROCK
sentiment 0.000
BREAKING NEWS: ALONGSIDE ANTHROPIC IPO, BERDICINE GOING BY THE $BER TICKET ON THE NASDAQ IS SET TO IPO SHORTLY AFTER MARKET OPEN. $980B WORTH OF SHARES HAVE BEEN LOADED IN ANTICIPATION THAT THIS COMPANY WILL CURE THE BER ILLNESS THAT HAS PLAGUED THE US- BLOOMBEERG
sentiment 0.281
Hang on a second....if every IPO was a rugpull this year, then it HAS to be different this time.
sentiment -0.250
THE KOSPI HAS MANAGED TO TURN GREEN
THIS IS NOT A DRILL, I REPEAT THIS IS NOT A DRILL
sentiment 0.000
No, the saying is FOUR years. Bitcoin's price has never been lower than it was 4 years ago.
Bitcoin's price HAS been lower than it was 5 years ago.
Bitcoin was $19k in December 2017. Bitcoin was $16k five years later in December 2022.
sentiment -0.080
The company may be hype, but calling their cars shit HAS to come from a place of either sour grapes or pure ignorance.
sentiment -0.846
https://imgur.com/a/Mq6JVgB
2019 Eagle “Kings Skull “ in the original packaging with COA, cool and unique coin $100 https://imgur.com/a/G3HLcGC
2017 1oz Australia GhostBusters coin in the original packaging with coa $100 https://imgur.com/a/qWy1ugF
2019 1oz Tuvalu Simpsons Duff beer bar in the original packaging with coa, cool and hard to find bar $150 https://imgur.com/a/Hs5Uf9K
2020 1oz Niue Justice league Aquaman in box with COA, very nice coin $100 https://imgur.com/a/rARGT7x
2024 Niue Agoro 1oz Mickey and Minnie Christmas ornament, nice looking coin $100 https://imgur.com/a/sgTPONU
2024 Niue Agoro 2oz Coco Remember me $180 https://imgur.com/a/5t38PZu
2024 Niue Agoro 2oz Iron man helmet, very nice looking piece $250 https://imgur.com/a/lBWelxQ
2021 Niue Star Wars Chibi 1oz coins in original packaging, Han Solo and Obi-Wan kenobi, $85 each https://imgur.com/a/xGVYnMH
2017 Falkland Islands 1oz silver Britannia with motto NGC graded PF69 $90 https://imgur.com/a/pvq8mBG
1/500th oz gold libertad design ICG ms70 $50 https://imgur.com/a/2lWtzP0
Zelle or Venmo payment between friends, I'll ship within 24hrs of receiving payment.
I will ship UPS insured for the value of the package (buyer pays) or you can decline insurance and I can ship USPS.
By choosing USPS Buyer assumes 100% liability after scanned in by USPS personnel, I will package well with plenty of bubble wrap and tape and help with any issues, I’ve shipped many packages without any issues so far AFTER SHIPPING OVER 1000 PACKAGES 1 HAS BEEN LOST BY THE USPS, check my feedback.
• USPS Ground Advantage — $6 (less than 3oz)
• USPS Priority $10
• USPS Priority Medium FRB — $20
sentiment 0.977
MU HAS DECLARED BANKRUPTCY. BETTER SELL EVERTHING NOW
sentiment 0.340
BRO YT HAS FINALLY HIT A HOME RUN AND RECOMMENDED THE 2000s GREATEST COUNTRY HITS
Years of terrible recommendations like 'the rise of anti-human design' and 'Skinty Fia full album' and 'How to apply game theory to your investment strategies' and I finally get one thats useful.
and also vintage 'santa sells camel smokes'
sentiment 0.868
